相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
Andreas H. Scheel et al.
HISTOPATHOLOGY (2018)
The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature.
Noha Abdelwahab Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
Robert M. Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
Alexander D. Le et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
Hee Kyung Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? (vol 15, 55, 2017)
Jordi Remon et al.
BMC MEDICINE (2017)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immunotherapy for Lung Cancer: No Longer an Abstract Concept
Kristen A. Marrone et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I. Rini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Michael Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G. McNeel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Mizuki Nishino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Update on New Therapies With Immune Checkpoint Inhibitors
Jennifer J. Peterson et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)
Harnessing the immune system to improve cancer therapy
Nikos E. Papaioannou et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment
Mizuki Nishino et al.
EUROPEAN JOURNAL OF RADIOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Non-Small-Cell Lung Cancer Role of the Immune System and Potential for Immunotherapy
David P. Carbone et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Immune modulation for cancer therapy
J. Naidoo et al.
BRITISH JOURNAL OF CANCER (2014)
MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
Leena Gandhi et al.
CANCER RESEARCH (2014)
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
Kim A. Reiss et al.
IMMUNOTHERAPY (2014)
New modalities of cancer treatment for NSCLC: focus on immunotherapy
Marianne Davies
CANCER MANAGEMENT AND RESEARCH (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L. Kaufman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)
Dorothy A. White et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention
V Mehta
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study
AL Thomas et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
